Phenomenex Inc.

Torrance, CA, United States

Phenomenex Inc.

Torrance, CA, United States

Time filter

Source Type

News Article | May 10, 2017
Site: www.marketwired.com

TORRANCE, CA--(Marketwired - May 09, 2017) - Phenomenex Inc., global leader in the research, design and manufacture of advanced technologies for the separation sciences, introduces new mixed-mode selectivities and particle sizes for UHPLC, HPLC and preparative work in the Luna column family. The first is the new Luna Omega Polar C18 stationary phase -- a unique selectivity on an innovative silica particle that delivers a wide elution window and combined high retention for polar and nonpolar analytes. This new phase is 100 percent aqueous-stable due to a polar-modified surface, providing flexibility in solvent and gradient system selection needed to achieve desired polar/non polar analyte separation. The Luna Omega Polar C18 is offered in a high-performance 1.6µm particle for UHPLC instruments as well as a low-pressure 5µm particle for direct scalability to analytical HPLC or preparative work. The 5µm particle is available in Phenomenex's patented Axia-packed preparative columns. Phenomenex is also introducing the 100 percent aqueous-stable Luna Omega PS C18 that delivers two distinct separation mechanisms at the same time. The particle surface of the PS C18 contains a positive charge that facilitates greater acidic compound retention through ionic interaction, while the C18 ligand delivers general reversed-phase retention. This mixed-mode selectivity is a valuable tool for greater separation between mixtures of compounds that have varying functional groups, such as peptides, pesticides or metabolite profiles. Additionally, the positive surface charge encourages excellent basic compound peak shape through the ionic repulsion of these compound species. Luna Omega columns are well suited for a wide range of applications including drug discovery and development, food contaminant analysis, environmental testing, toxicology and clinical research. "Our Luna HPLC brand is one of the most recognized in the global chromatography industry, with a 20-year track record," commented Simon Lomas, strategic marketing manager for Phenomenex. "The recent expansion of this column family with novel Luna Omega silica particle technology and mixed-mode polar stationary phases has enabled us to bring the Luna legacy to the UHPLC world." Phenomenex Kinetex® Core-Shell Technology and Luna Omega columns together provide an ideal complementary UHPLC solution for greater efficiency and separation power. With a growing range of valuable selectivities, this pairing of core-shell and fully porous UHPLC products affords customers a better choice for immediate gains in productivity, resolution and retention. Combining the Luna Omega Polar C18 with the previously released fully porous Luna Omega 1.6µm C18 and Kinetex 1.7µm core-shell phases further expands the options for UHPLC method development and improvement. Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.


News Article | May 12, 2017
Site: www.marketwired.com

TORRANCE, CA--(Marketwired - May 12, 2017) - Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces the Kinetex 2.6 µm Polar C18 -- the ninth selectivity in the Kinetex core-shell family. This stationary phase combines C18 ligands with a polar-modified surface to enable superior retention of polar and nonpolar compounds while ensuring 100 percent aqueous stability. Incorporating the key performance benefits of the Kinetex Core-Shell Technology, the 2.6 µm Polar C18 particle size provides high efficiency and performance on HPLC systems and potential increases in resolution, sensitivity and separation speed. On UHPLC systems, the 2.6 µm size provides comparable performance to fully porous sub-2 µm particles, but at much lower backpressure levels. With this new Kinetex particle, Phenomenex now offers the dual polar/nonpolar selectivity of the Polar C18 stationary phase in two particle types -- Kinetex core-shell and Luna Omega thermally modified fully porous. This enables researchers to move back and forth between two different solid supports to better address method development needs and wants. "We are pleased to extend the performance and sensitivity of our Kinetex Core-Shell Technology products to the challenges of retaining and analyzing polar compounds," comments Simon Lomas, strategic marketing manager for Phenomenex. "This new selectivity greatly enhances polar/nonpolar retention compared to traditional alkyl phases and gives customers a versatile product with which they can start reversed phase method development." The new Kinetex Polar C18 is an ideal all-purpose phase for use with mixtures of multiple polar and nonpolar compounds or single-class methods with closely related compounds, such as impurities or metabolites. Key applications that can greatly benefit from this dual selectivity include pesticide screening in food, testing of emerging environmental contaminants and drug analysis in pharmaceutical discovery, toxicology testing and clinical research. For more information, visit www.phenomenex.com/kinetex. Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.


TORRANCE, CA--(Marketwired - May 11, 2017) - Phenomenex Inc., global leader in the research, design and manufacture of advanced technologies for the separation sciences, introduces two new particle chemistries for the characterization and purification of synthetic oligonucleotides. Joining the company's Clarity BioSolutions portfolio are Clarity Oligo-XT, for high-efficiency reversed-phase LC analysis and purification, and Clarity Oligo-SAX, a high-resolution strong anion exchanger (SAX) for characterization. Phenomenex Clarity BioSolutions, first introduced almost a decade ago, are used in pharmaceutical labs and contract research organizations (CROs) where synthetic oligonucleotide-based therapeutics are being developed and tested, as well as in the labs of custom oligonucleotide and nucleic acid manufacturers. Synthetic oligonucleotides are growing in popularity as novel agents for the treatment of disease, and liquid chromatography continues to be an effective tool for characterization, with technology advancements that address improvements in resolution, throughput and column lifetime. The new Clarity Oligo-XT C18 columns feature novel and robust core-shell media, for high-efficiency reversed-phase characterization of synthetic DNA and RNA, pH stability from 1 to 12 and increased sensitivity that improves quantitation by mass spectrometry (MS). These core-shell particles deliver the separation power necessary to accurately resolve closely related synthetic oligonucleotide sequences. Clarity Oligo-XT columns are available in directly scalable 1.7µm, 2.6µm and 5µm particle sizes that enable easy method transfer between analytical HPLC/UHPLC instrumentation and preparative purifications systems. The 5µm particle is available in Phenomenex's patented Axia-packed preparative columns that increase purification performance. The Clarity Oligo-SAX columns feature an entirely new, rugged non-porous particle that retains synthetic oligonucleotides through strong ion exchange mechanisms, adding a robust strong anion exchanger choice with improved column lifetimes to the Clarity family. These quaternary amine functionalized, nonporous particles are engineered for performance at high pH (2.5 to 12.5) and temperatures up to 85 ˚C and are provided in 5µm particle size for analytical characterization. "Our synthetic oligonucleotide characterization products are solution-based and have been developed to meet our customers' evolving needs," said Simon Lomas, strategic marketing manager for Phenomenex. "The Oligo-XT and Oligo-SAX columns allow customers to capitalize on both reversed-phase and ion exchange chromatography to get greater separation, faster analyses and extended column lifetimes." Phenomenex's Clarity BioSolutions product portfolio delivers purified synthetic oligonucleotides in a range of formats and scales to meet the specific demands of the industry. From simple desalting, to rapid isolation of oligonucleotide therapeutics from biological samples, to high-throughput, high-purity purification techniques, the Clarity BioSolutions portfolio offers a comprehensive approach. Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.


TORRANCE, CA--(Marketwired - May 18, 2017) - Phenomenex Inc., global leader in the research, design and manufacture of advanced technologies for the separation sciences, is introducing two new offerings to its Luna Omega fully porous LC column line -- the Luna Omega 3 µm Polar C18 and the Luna Omega 3 µm PS C18. The Luna Omega Polar C18 stationary phase is a unique, robust selectivity bonded to an innovative silica particle that delivers high loadability and retention for both polar and nonpolar analytes. This new phase is 100 percent aqueous-stable due to a polar-modified surface, providing flexibility in solvent and gradient system selection needed to achieve desired polar/nonpolar analyte separation. The new 3 µm particle joins the existing 1.6 µm and 5 µm sizes to provide full scalability from UHPLC to HPLC to preparative chromatography. Unlike a traditional C18, the Luna Omega PS C18 delivers two distinct and useful separation mechanisms and offers 100 percent aqueous stability. The particle surface of the PS C18 contains a positive charge that facilitates greater acidic compound retention through ionic interaction, while the C18 ligand delivers general reversed-phase retention. This mixed-mode selectivity is a valuable tool for greater separation between mixtures of compounds that have varying functional groups, such as peptides, pesticides or metabolite profiles. Additionally, the positive surface charge encourages sharp basic compound peak shape through the ionic repulsion of these compound species. Like the Luna Omega Polar C18, the three PS 18 particle size choices enable full scalability from UHPLC to HPLC to preparative chromatography. Luna Omega columns are well suited for a wide range of applications including drug discovery and development, food contaminant analysis, environmental testing, toxicology and clinical research. "With three directly scalable particle sizes, chromatographers can easily take advantage of the enhanced retention of the Polar C18 and PS C18 for their HPLC and UHPLC work," commented Simon Lomas, strategic marketing manager for Phenomenex. "These new selectivities offer our customers high-efficiency solutions for their large range of work, from routine/general purpose to complex analyses." For more information, visit www.phenomenex.com/lunaomega. Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and wellbeing. For more information please visit www.phenomenex.com and follow the company's blog at www.scienceunfiltered.com Link to this release at: https://www.phenomenex.com/Home/News?id=New_3_µm_Particle_Size_Adds_HPLC_Scalability_to_Luna_Omega_Mixed-Mode_Selectivities Please send READER INQUIRIES from this news release directly to: info@phenomenex.com


News Article | May 27, 2017
Site: www.marketwired.com

TORRANCE, CA--(Marketwired - May 27, 2017) - Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the opening of a new manufacturing and development facility dedicated to the company's gas chromatography (GC) columns, marketed under the Zebron™ brand name. The 15,000-square-foot facility, which was designed and extensively renovated specifically for Phenomenex, is located in the Sacramento, Calif. suburb of El Dorado Hills. Prior to the expansion, GC products were manufactured in Sutter Creek, Calif. The new location supports twice the production capacity and enables improved logistics and delivery speeds to the company's global customers. Phenomenex is currently expanding sales internationally as demand for GC columns grows in North America and Europe as well as in India and China, particularly in food testing applications. "The Phenomenex GC manufacturing and development operation has a rich and long history," comments Emmet Welch, senior product development manager for Phenomenex. "We are staffed with scientists and production experts with decades of leadership in every aspect of GC column technology and manufacturing. In fact, many of our current staff have more than 25 years experience in column technology development." The new facility includes organic synthesis, R&D and analytical labs. "Detailed and exhaustive planning went into creating an efficient production floor, using lean principles to maximize the use of space while minimizing the movement of people and materials. We have also included a centralized piping system that reduces the cost and movement of process gasses," continued Welch. "With advanced, automated workflows, this new facility will be capable of supporting significant growth in Phenomenex GC manufacturing and new product development for many years." The facility's work environment for employees features a bright, colorful and open design, complete with inspiring, art-filled spaces and an outside athletic center. Phenomenex founder, Fasha Mahjoor, remarked, "Phenomenex is known for the vibrant colors and pleasing architectural spaces that are the hallmarks of our corporate headquarters. Our people are the reason for our success, and it's our goal and responsibility to give them an environment that inspires teamwork and camaraderie and promotes their health and well-being." About Phenomenex Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and wellbeing. For more information please visit www.phenomenex.com and follow the company's blog at www.scienceunfiltered.com


News Article | May 26, 2017
Site: www.marketwired.com

TORRANCE, CA--(Marketwired - May 26, 2017) - Phenomenex Inc., a global leader in the research, design and manufacture of advanced technologies for the separation sciences, introduces a trio of Zebron™ GC columns specially developed for the analysis of fatty acid methyl esters (FAME) in food. Identification and measurement of these compounds in food products such as cheese, peanut butter, infant formula, cooking oils and oil-based nutritional supplements is increasingly important in meeting labeling requirements and testing for product adulteration. The Zebron ZB-FAME leads the new trio of Phenomenex GC columns. This stationary phase offers selectivity targeting a 37-compound mix, in a column that's much shorter than traditional solutions. The shorter column reduces run times to about 11 minutes -- a decrease of 75 percent or more -- while still providing R values of 1.0 or greater. Its optimized high-cyanopropyl chemistry delivers the required high polarity for the separation of cis/trans FAME isomers and meets the guidelines of AOAC, AOCS and IOC methods. Zebron ZB-FAME columns also come with a guarantee based on Phenomenex' unique QC testing protocols, where every column is individually QC-tested against the target 37 compounds for FAME analysis. "Cis/trans FAME analysis has historically been carried out with long columns, which produce corresponding long run times," explained Kristen Parnell, product marketing manager for Phenomenex. "With our innovative new chemistry, we've been able to improve the separations to such a degree that they can be carried out on far shorter columns, saving analysts up to 45 minutes per run." The new chemistry is stable enough to withstand temperatures as high as 280 ˚C, enabling inclusion of column baking steps to remove contaminants traditionally left behind when analyzing food samples, improving column lifetime. Second in the new trio is Zebron ZB-88 -- a new GC alternative to other 88-phase columns for the separation of cis/trans isomers. This column is well suited for the analysis of olive and hydrogenated oils. The third new column, Zebron ZB-23, is a cost-effective alternative to existing 23-phase columns for the separation of cis/trans isomers in a group of products that includes omega-3 and fish oils. Both the ZB-88 and ZB-23 columns can be used in direct substitution for traditional products recommended for use with regulatory methods. "These three new columns for FAME analysis add to the portfolio we already have in place for food testing," said Parnell. "Our focus is on keeping our ears to the ground in this dynamic industry, listening to the evolving needs of customers and developing innovative solutions to meet them." Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex. Attached: Photo Link to this release at: http://www.phenomenex.com/Home/News?id=New_Family_of_Zebron_GC_Columns_for_Fast_Highly_Selective_FAME_Analysis Please send READER INQUIRIES from this news release directly to: info@phenomenex.com


A slurry chamber is fastened to and held in coaxial alignment with a chromatography column by a V-band. One end of the column has an end cap and fit. A slurry of fluid and chromatographic media is placed in the column and chamber. A piston is forced through the chamber and into the column by a hydraulic ram to expel the fluid and form a media bed in the column. The slurry chamber is removed, and a split end cap is fastened to the column. A threaded recess in the split end cap receives a split, threaded collet. The collet is tightened until it pushes against the piston with the same force as the ram, at which point the ram is released and the column removed for use.


Patent
Phenomenex Inc. | Date: 2010-01-22

A slurry chamber is fastened to and held in coaxial alignment with a chromatography column by a V-band. One end of the column has an end cap and frit. A slurry of fluid and chromatographic media is placed in the column and chamber. A piston is forced through the chamber and into the column by a hydraulic ram to expel the fluid and form a media bed in the column. The slurry chamber is removed, and a split end cap is fastened to the column. A threaded recess in the split end cap receives a split, threaded collet. The collet is tightened until it pushes against the piston with the same force as the ram, at which point the ram is released and the column removed for use.


Patent
Phenomenex Inc. | Date: 2013-03-15

A chromatography column has an upstream frit made of non-woven, metal fibers sintered to form a depth filter having graded interstitial passages increasing in size in the direction of flow through the column during use. The frit is held in the column or in a recess of an end fitting, insert or PEEK holder. An annular PEEK ring seals at least one face of the frit at a peripheral edge of the frit, and preferably seals both faces at that edge.


Patent
Phenomenex Inc. | Date: 2012-11-02

A blood sampling device is provided having holder with a manipulating end and an absorbent probe on the opposing end. The probe is of hydrophilic polymer sized to directly absorb a predetermined volume of up to about 30 microliters of blood. Ribs on the holder position the probe within a compartment of a container to prevent contact with the container. The ribs also position the probe within extraction wells.

Loading Phenomenex Inc. collaborators
Loading Phenomenex Inc. collaborators